Functional characterization of a human cyclin T1 mutant reveals a different binding surface for Tat and HEXIM1

Virology

Volumn 426, Issue 2, 2012, Pages 152-161

  Kuzmina, Alona ^a   Hadad, Uzi ^a   Fujinaga, Koh ^b   Taube, Ran ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cdk9; Cyclin T1; Hexamethylene bisacetamide inducible protein 1 (HEXIM1); HIV; Positive transcription elongation factor b (P TEFb); Tat

Indexed keywords

BINDING PROTEIN; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; CYCLIN T1 U7; HEXAMETHYLENE BISACETAMIDE INDUCIBLE PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; MYOCYTE ENHANCER FACTOR 2; PROTEIN MEF2C; TRANSACTIVATOR PROTEIN; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION ELONGATION FACTOR B; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS TRANSCRIPTION;

CD4-POSITIVE T-LYMPHOCYTES; CYCLIN T; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RNA-BINDING PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84857781378     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.01.033     Document Type: Article

References (41)

1. Anand K., Schulte A., Fujinaga K., Scheffzek K., Geyer M. Cyclin box structure of the P-TEFb subunit cyclin T1 derived from a fusion complex with EIAV tat. J. Mol. Biol. 2007, 370(5):826-836.
2. Anand K., Schulte A., Vogel-Bachmayr K., Scheffzek K., Geyer M. Structural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAV. Nat. Struct. Mol. Biol. 2008, 15(12):1287-1292.
3. Asamitsu K., Hibi Y., Imai K., Victoriano A.F., Kurimoto E., Kato K., Okamoto T. Functional characterization of human cyclin T1 N-terminal region for human immunodeficiency virus-1 Tat transcriptional activation. J. Mol. Biol. 2011, 410(5):887-895.
4. Barboric M., Peterlin B.M. A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLoS Biol. 2005, 3(2):e76.
5. Barboric M., Nissen R.M., Kanazawa S., Jabrane-Ferrat N., Peterlin B.M. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol. Cell 2001, 8(2):327-337.
6. Baumli S., Lolli G., Lowe E.D., Troiani S., Rusconi L., Bullock A.N., Debreczeni J.E., Knapp S., Johnson L.N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J. 2008, 27(13):1907-1918.
7. Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., Peterlin B.M., Price D.H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 2000, 275(37):28345-28348.
8. Chen R., Yang Z., Zhou Q. Phosphorylated positive transcription elongation factor b (P-TEFb) is tagged for inhibition through association with 7SK snRNA. J. Biol. Chem. 2004, 279(6):4153-4160.
9. Fuda N.J., Ardehali M.B., Lis J.T. Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature 2009, 461(7261):186-192.
10. Fujinaga K., Irwin D., Geyer M., Peterlin B.M. Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression. J. Virol. 2002, 76(21):10873-10881.
11. Garber M.E., Wei P., KewalRamani V.N., Mayall T.P., Herrmann C.H., Rice A.P., Littman D.R., Jones K.A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 1998, 12(22):3512-3527.
12. Garber M.E., Mayall T.P., Suess E.M., Meisenhelder J., Thompson N.E., Jones K.A. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol. Cell. Biol. 2000, 20(18):6958-6969.
13. Gargano B., Amente S., Majello B., Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle 2007, 6(16):2031-2037.
14. Hah N., Danko C.G., Core L., Waterfall J.J., Siepel A., Lis J.T., Kraus W.L. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 2011, 145(4):622-634.
15. Ho D.D., Bieniasz P.D. HIV-1 at 25. Cell 2008, 133(4):561-565.
16. Hwang S., Tamilarasu N., Kibler K., Cao H., Ali A., Ping Y.H., Jeang K.T., Rana T.M. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 2003, 278(40):39092-39103.
17. Jadlowsky J.K., Nojima M., Schulte A., Geyer M., Okamoto T., Fujinaga K. Dominant negative mutant cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat. Retrovirology 2008, 5:63.
18. Kanazawa S., Okamoto T., Peterlin B.M. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 2000, 12(1):61-70.
19. Li Q., Price J.P., Byers S.A., Cheng D., Peng J., Price D.H. Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186. J. Biol. Chem. 2005, 280(31):28819-28826.
20. Lind K.E., Du Z., Fujinaga K., Peterlin B.M., James T.L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol. 2002, 9(2):185-193.
21. Michels A.A., Nguyen V.T., Fraldi A., Labas V., Edwards M., Bonnet F., Lania L., Bensaude O. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol. Cell. Biol. 2003, 23(14):4859-4869.
22. Michels A.A., Fraldi A., Li Q., Adamson T.E., Bonnet F., Nguyen V.T., Sedore S.C., Price J.P., Price D.H., Lania L., Bensaude O. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J. 2004, 23(13):2608-2619.
23. Mischiati C., Jeang K.T., Feriotto G., Breda L., Borgatti M., Bianchi N., Gambari R. Aromatic polyamidines inhibiting the Tat-induced HIV-1 transcription recognize structured TAR-RNA. Antisense Nucleic Acid Drug Dev. 2001, 11(4):209-217.
24. Napolitano G., Mazzocco A., Fraldi A., Majello B., Lania L. Functional inactivation of Cdk9 through oligomerization chain reaction. Oncogene 2003, 22(31):4882-4888.
25. Nguyen V.T., Kiss T., Michels A.A., Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001, 414(6861):322-325.
26. Nojima M., Huang Y., Tyagi M., Kao H.Y., Fujinaga K. The positive transcription elongation factor b is an essential cofactor for the activation of transcription by myocyte enhancer factor 2. J. Mol. Biol. 2008, 382(2):275-287.
27. Ott M., Geyer M., Zhou Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 2011, 10(5):426-435.
28. Peterlin B.M., Price D.H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 2006, 23(3):297-305.
29. Richter S.N., Palu G. Inhibitors of HIV-1 Tat-mediated transactivation. Curr. Med. Chem. 2006, 13(11):1305-1315.
30. Schulte A., Czudnochowski N., Barboric M., Schonichen A., Blazek D., Peterlin B.M., Geyer M. Identification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat. J. Biol. Chem. 2005, 280(26):24968-24977.
31. Simone C., Bagella L., Bellan C., Giordano A. Physical interaction between pRb and cdk9/cyclinT2 complex. Oncogene 2002, 21(26):4158-4165.
32. Simone C., Stiegler P., Bagella L., Pucci B., Bellan C., De Falco G., De Luca A., Guanti G., Puri P.L., Giordano A. Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene 2002, 21(26):4137-4148.
33. Tahirov T.H., Babayeva N.D., Varzavand K., Cooper J.J., Sedore S.C., Price D.H. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2010, 465(7299):747-751.
34. Taube R., Fujinaga K., Irwin D., Wimmer J., Geyer M., Peterlin B.M. Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J. Virol. 2000, 74(2):892-898.
35. Tyagi M., Pearson R.J., Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 2010, 84(13):6425-6437.
36. Wei P., Garber M.E., Fang S.M., Fischer W.H., Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998, 92(4):451-462.
37. Yang Z., Zhu Q., Luo K., Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 2001, 414(6861):317-322.
38. Yik J.H., Chen R., Nishimura R., Jennings J.L., Link A.J., Zhou Q. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol. Cell 2003, 12(4):971-982.
39. Yik J.H., Chen R., Pezda A.C., Samford C.S., Zhou Q. A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb. Mol. Cell. Biol. 2004, 24(12):5094-5105.
40. Yik J.H., Chen R., Pezda A.C., Zhou Q. Compensatory contributions of HEXIM1 and HEXIM2 in maintaining the balance of active and inactive positive transcription elongation factor b complexes for control of transcription. J. Biol. Chem. 2005, 280(16):16368-16376.
41. Zhou Q., Yik J.H. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev. 2006, 70(3):646-659.